<rows>
  <row id="1143447" langcode="en">
    <body><![CDATA[<div class="rxbodyfield">
<p>Find out more about what we do, who we are, and how to contact us for more information.</p>
</div>]]></body>
  </row>
  <row id="1143502" langcode="en">
    <body><![CDATA[<div class="rxbodyfield">
<p>The MyPART network works best when everyone works together. We need patients, families, and advocacy organizations to help us learn as much as we can about rare cancers. Learn more about how you can participate in MyPART&rsquo;s work to improve the lives of children, teens, and young adults with rare cancers.</p>
</div>]]></body>
  </row>
  <row id="1143525" langcode="en">
    <body><![CDATA[<div class="rxbodyfield">
<p>Rare tumors can form anywhere in the body. MyPART is studying tumors in several different body systems.</p>
</div>]]></body>
  </row>
  <row id="1143526" langcode="en">
    <body><![CDATA[<div class="rxbodyfield">
<p>Research is key to finding new treatments for rare cancers. Researchers studying rare cancers face a lot of challenges. MyPART is working to address these challenges&nbsp;in hopes of&nbsp;finding new treatments faster.</p>
</div>]]></body>
  </row>
  <row id="1143528" langcode="en">
    <body><![CDATA[<div class="rxbodyfield">
<p>MyPART hosts events and participates in scientific conferences that help promote rare tumor research. Check back often to read news about MyPART activities and upcoming events.</p>
</div>]]></body>
  </row>
  <row id="1165882" langcode="en">
    <body><![CDATA[<div class="rxbodyfield">
<p>Recent news about the MyPART program and other advances in the study of rare tumors.</p>
<p></p>
<div sys_dependentvariantid="2088" sys_dependentid="1147225" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="305" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="&lt;div sys_dependentvariantid=&quot;2088&quot; sys_dependentid=&quot;1147228&quot; inlinetype=&quot;rxvariant&quot; rxinlineslot=&quot;105&quot; sys_siteid=&quot;305&quot; class=&quot;rx_ephox_inlinevariant mceNonEditable&quot; contenteditable=&quot;false&quot; rxselectedtext=&quot;&quot;&gt;
&lt;figure class=&quot;image-left-small centered-set&quot;&gt;
&lt;div class=&quot;centered-element&quot;&gt;&lt;img src=&quot;https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;amp;sys_authtype=0&amp;amp;sys_variantid=1482&amp;amp;sys_context=0&amp;amp;sys_folderid=1145880&amp;amp;sys_siteid=305&amp;amp;sys_contentid=1147225&amp;amp;sys_command=edit&quot; alt=&quot;Chordoma Clinic Participants Talking&quot; /&gt;&lt;!--Comment--&gt;&lt;/div&gt;
&lt;/figure&gt;
&lt;/div&gt;" sys_relationshipid="7359888">
<figure class="image-left-small centered-set">
<div class="centered-element"><img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=1&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=1145880&amp;sys_siteid=305&amp;sys_contentid=1147225&amp;sys_command=edit" alt="Chordoma Clinic Group" /><!--Comment--></div>
<figcaption>
<div class="caption-container no-resize">
<p>Chordoma Clinic Group, April 2019</p>
</div>
</figcaption>
</figure>
</div>
<p></p>
<h2></h2>
<h2><a href="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_context=0&amp;sys_authtype=0&amp;sys_siteid=305&amp;sys_variantid=2297&amp;sys_contentid=1147224" sys_dependentvariantid="2297" sys_dependentid="1147224" inlinetype="rxhyperlink" rxinlineslot="103" sys_siteid="305" sys_relationshipid="7359885" sys_variantid="2297" sys_contentid="1147224">First Chordoma Clinic Brings Together Patients, Families, and Expert Doctors</a></h2>
<p>MyPART, Center for Cancer Research, and the Chordoma Foundation collaborated to host the first childhood, teen, and young adult Chordoma Clinic at NIH from April 16th to 18th, 2019. The clinic aimed to share knowledge and to collect data for research on chordoma affecting young people.</p>
<p><em>April 19, 2019</em></p>
<p></p>
<hr />
<p></p>
<div sys_dependentvariantid="2088" sys_dependentid="1145883" inlinetype="rxvariant" rxinlineslot="105" sys_siteid="305" class="rx_ephox_inlinevariant mceNonEditable" contenteditable="false" rxselectedtext="" sys_relationshipid="7359889">
<figure class="image-left-small centered-set">
<div class="centered-element"><img src="https://percussion.cancer.gov:443/Rhythmyx/assembler/render?sys_revision=2&amp;sys_authtype=0&amp;sys_variantid=1482&amp;sys_context=0&amp;sys_folderid=1145880&amp;sys_siteid=305&amp;sys_contentid=1145883&amp;sys_command=edit" alt="a child sitting on the floor drawing" /><!--Comment--></div>
<figcaption>
<div class="caption-container no-resize">
<div class="image-photo-credit">Credit: National Cancer Institute</div>
</div>
</figcaption>
</figure>
</div>
<p></p>
<h2><a href="https://ccr.cancer.gov/news/article/mek-inhibitor-selumetinib-granted-breakthrough-designation-by-fda-to-treat-neurofibromatosis-type-one-in-pediatric-patients">MEK inhibitor selumetinib granted breakthrough designation by FDA to treat neurofibromatosis type 1 in pediatric patients</a></h2>
<p>Selumetinib, a treatment for Neurofibromatosis Type 1, was given a breakthrough designation by the FDA to treat pediatric patients.</p>
<p><em>CCR News Headlines - April 12, 2019</em></p>
</div>]]></body>
  </row>
</rows>